flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it has successfully enrolled the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898).
CMAST: New partnership launched to facilitate the development of new drugs for children across Europe
conect4children (c4c) is a large collaborative paediatric network that will facilitate the development of new drugs and other therapies for children in Europe. In support of Janssen, CMAST – a leading consultancy and project management company in life sciences - is involved in this six-year project. The kick-off meeting, taking place from May 23rd to May 25th at Bayer AG in Berlin (Germany), brings together key stakeholders across academia and industry.
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group (EASDec) Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland.
Imec Presents Novel Organ-on-Chip Platform for Drug Screening
Imec, the world-leading research and innovation hub in nano-electronics and digital technologies, presents this week at its technology forum ITF 2018 (Antwerp, May 23-24), a novel organ-on-chip platform for pharmacological studies with unprecedented signal quality. It fuses imec’s high-density multi-electrode array (MEA)-chip with a microfluidic well plate, developed in collaboration with Micronit Microtechnologies, in which cells can be cultured, providing an environment that mimics human physiology. Capable of performing multiple tests in parallel, the new device aims to be a game-changer for the pharmaceutical industry, offering high quality data in the drug development process.